Our advisory board member, Paul Fehlner, has written an insightful article about IP and open innovation in Pharma.

It is important to note that designing the right amount of openness is often based on IP, not against IP. In the times of COVID19, the need for openness increases, but can easily be managed together with the IP system in combination with clever contractual solutions as this article explains.

You can read the article here